Bioquark Inc., Organ Regeneration and Tissue Repair Company, Retains JSBarkats PLLC for Public Offering and PIPE Financing

Mar 21, 2012, 11:14 ET from Bioquark Inc.

TAMPA, Fla., March 21, 2012 /PRNewswire/ -- Bioquark Inc., (www.bioquark.com) a biopharmaceutical company developing proprietary biological drugs for regeneration and repair of human organs and tissues, announced today that it has retained the services of JSBarkats PLLC to represent Bioquark in all aspects of the company's SEC compliance and securities legal work, as well as help with structuring future financing for the company.

"We are pleased to be working with the seasoned group of professionals at JSBarkats," said Ira S. Pastor, CEO of Bioquark Inc. "Their combination of experience in both corporate and securities law, as well as the team of specialists covering the life sciences sector, including experience in regenerative medicine and biotech intellectual property, make them an ideal partner for Bioquark Inc."

Of the $2.6 trillion annual U.S. healthcare bill, the majority that is spent on direct patient care is focused on diseases with a cell damage or degeneration component.

Unfortunately, the current therapeutic tools to address these needs, including organ transplantation, pharmaceuticals, and more recently stem cell therapies, are insufficient solutions.

Organ transplantation is limited by a substantial and growing donor gap, as well as the unavoidable host-versus-graft reaction.  Pharmaceuticals, while capable of interfering and slowing down degenerative processes, can do nothing to reverse cell damage once it has occurred.  Even the evolving stem cell space is running into many technical, efficacy, and regulatory challenges which will substantially limit the potential of the market for these replacement therapies.

"Alternative approaches are required that can simultaneously address both regeneration and repair therapeutic indications, leverage existing pharmaceutical regulatory pathways, and avoid the many flaws in the industry's current offerings, all while doing so in a cost efficient manner," said Pastor. "Coordinating our cutting edge R&D program with a disciplined capital markets approach will rapidly advance our ability to develop and commercialize these therapies in the U.S. and around the world."

About Bioquark Inc. www.bioquark.com 

Bioquark Inc., a biopharmaceutical company, is focused on developing proprietary biological drugs that can be simultaneously leveraged for both the regeneration and repair of complex human organs and tissues.  The company is currently developing its lead biologic, BQ-A, which has demonstrated a direct reprogramming and remodeling effect on diseased or damaged cells in living organisms, creating tissue-specific micro-environments that provide for both efficient regeneration and repair. These micro-environments mimic those seen during normal human morphogenic development, as well as during amphibian limb regeneration. Developed as a biologic, BQ-A will be more amenable to existing regulatory pathways, and avoids flaws in the industry's current heavy emphasis on stem cells and tissue engineering.  With annual combined costs of organ transplantation, organ replacement, and medical care / pharmaceuticals for diseases that lead to organ failure, representing a substantial portion of the $2.6 trillion U.S. healthcare bill alone, BQ-A represents a lucrative and transformational therapeutic opportunity.

About JSBarkats PLLC, and Mr. Barkats. www.JSBarkats.com 

JSBarkats PLLC is a dynamic full-service law firm headquartered in the heart of Manhattan, specializing in Corporate, Capital Markets and Securities law. The firm provides experienced, efficient, and cost-effective legal services to institutional as well as small and mid-sized corporate clients and individuals. JSBarkats, principally represents both established and publicly traded emerging growth companies, both domestic and foreign, in a wide variety of industries. With 25 attorneys located in NY, Alabama, Florida and Connecticut the firm's synergy between its strong commercial litigation and its experienced corporate team represents venture capital firms, start-ups, investment banking institutions, broker dealers, and high net worth individuals and other investors. The firm specializes  in private placements, mergers, acquisitions and dispositions, SEC compliance, public offerings, general 1933 and 1934 Act matters and strategic business relationships. JSBarkats' attorneys, under the leadership of Mr. Barkats also represents issuers, underwriters, placement agents and others as well as lenders and financial participants, in mergers and acquisitions, IPOs, private equity, private placements and PIPE transactions.

Contact:

Ira S. Pastor
CEO
Bioquark Inc.
267-971-7725
pastor@bioquark.com

SOURCE Bioquark Inc.



RELATED LINKS

http://www.bioquark.com